Endoscopic Submucosal Dissection Using EndoTrac, a Novel Traction Device

Digestion. 2021;102(5):714-721. doi: 10.1159/000511731. Epub 2020 Dec 22.


Background: Endoscopic submucosal dissection (ESD) is recognized as a minimally invasive and curative treatment for superficial gastrointestinal (GI) cancers. However, ESD is still challenging and time-consuming with a high risk of adverse events such as bleeding and perforation. Various traction methods have been explored for maintaining good visualization of the submucosal layer during ESD. We developed a novel traction device (the EndoTrac) which can easily tie the thread and has the ability to change the towing direction. The aim of this study is to evaluate safety and feasibility of ESD using the EndoTrac for GI neoplasms.

Patients and methods: We retrospectively analyzed 44 patients (45 lesions) with esophageal, gastric, duodenal, and colorectal neoplasms who had undergone ESD using the EndoTrac device between June 2018 and May 2019. Primary outcome measures were preparation time, procedural success using the EndoTrac device, and ease of ability to change towing direction.

Results: Mean preparation time was 2 (2-5) min in esophagus, 3 (1-5) min in stomach, 6 (5-9) min in duodenum, and 4 (2-8) min in colorectum. The procedural success rate was 100% (8/8) in esophagus, 100% (21/21) in stomach, 100% (4/4) in duodenum, and 100% (12/12) in colorectum. The rate of successful towing to both proximal and distal sides was 100% (8/8) in esophagus, 100% (21/21) in stomach, 0% (0/4) in duodenum, and 100% (12/12) in colorectum.

Conclusions: Use of the EndoTrac device appears to be a feasible approach to ESD for GI neoplasms.

Keywords: Device; Endoscopic submucosal dissection; Gastrointestinal cancers; Minimally invasive.

MeSH terms

  • Colorectal Neoplasms* / surgery
  • Endoscopic Mucosal Resection* / adverse effects
  • Humans
  • Retrospective Studies
  • Traction
  • Treatment Outcome